Cellebrite DI (CLBT) Stock Price, News & Analysis

Company Overview

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows. Cellebrite DI also provides cloud collection tools to access data stored in online accounts and a suite of analytical modules that facilitate link analysis, timeline reconstruction and cross-case comparison. These solutions are complemented by professional services, training programs and technical support to ensure organizations can deploy and operate the technology effectively.

Founded in 1999 and headquartered in Petah Tikva, Israel, Cellebrite DI maintains key regional offices in North America, EMEA and APAC to serve a diverse global customer base. The company has played a role in high-profile forensic investigations, compliance audits and cybersecurity operations across multiple continents. Over time, it has expanded its portfolio through targeted research and development, strategic partnerships and acquisitions aimed at advancing its digital intelligence capabilities and addressing emerging challenges in data privacy and security.

Under the leadership of President and Chief Executive Officer Yossi Carmil, Cellebrite DI is governed by a board of directors chaired by cybersecurity veteran Amit Yoran. The management team combines expertise in digital forensics, software engineering and law enforcement to drive product innovation and maintain rigorous standards for data integrity and chain of custody. Through ongoing investment in R&D and a focus on customer-centric solutions, Cellebrite DI continues to evolve its offering to meet the needs of investigators and risk-management professionals worldwide.

Key Stats

• Today's Range: $10.78 to $11.20
• 50-Day Range: $10.80 to $16.61
• 52-Week Range: $9.58 to $19.98
• Volume: 7.84 million shs
• Average Volume: 2.97 million shs
• Market Capitalization: $2.78 billion
• P/E Ratio: 50.64
• Dividend Yield: N/A
• Price Target: $16.70
• Consensus Rating: Moderate Buy

Cellebrite DI Stock Analysis - MarketRank™

Cellebrite DI scored higher than 87% of companies evaluated by MarketBeat, and ranked 109th out of 602 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellebrite DI has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cellebrite DI has a consensus price target of $16.70, representing about 49.9% upside from its current price of $11.14.

Amount of Analyst Coverage

Cellebrite DI has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 26.83%

Earnings Growth

Earnings for Cellebrite DI are expected to grow by 26.83% in the coming year, from $0.41 to $0.52 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellebrite DI is 50.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellebrite DI is 50.64, which means that it is trading at a less expensive P/E ratio than the Technology sector average P/E ratio of about 75.42.

Price to Earnings Growth Ratio

Cellebrite DI has a PEG Ratio of 1.38. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cellebrite DI has a P/B Ratio of 5.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.47% of the float of Cellebrite DI has been sold short.

Short Interest Ratio / Days to Cover

Cellebrite DI has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Cellebrite DI has recently increased by 16.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellebrite DI does not currently pay a dividend.

Dividend Growth

Cellebrite DI does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.14

News Sentiment

Cellebrite DI has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Technology companies.

News Coverage This Week

MarketBeat has tracked 40 news articles for Cellebrite DI this week, compared to 4 articles on an average week.

Search Interest

16 people have searched for CLBT on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

7 people have added Cellebrite DI to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cellebrite DI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,631,972.00 in company stock.

Percentage Held by Insiders

5.70% of the stock of Cellebrite DI is held by insiders.

Percentage Held by Institutions

45.88% of the stock of Cellebrite DI is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: NASDAQ:CLBT
• CIK: 1854587
• Web: www.cellebrite.com
• Phone: 972-73-394-8000
• Fax: 972-3924-7104
• Employees: 1,285
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cellebrite DI: $16.70
• High Price Target: $25.00
• Low Price Target: $12.50
• Potential Upside/Downside: +49.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.22
• Trailing P/E Ratio: 50.64
• Forward P/E Ratio: 27.17
• P/E Growth: 1.38
• Net Income: $78.33 million
• Net Margins: 11.43%
• Pretax Margin: 17.12%
• Return on Equity: 16.04%
• Return on Assets: 8.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.54
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: $514.29 million
• Price / Sales: 5.40
• Cash Flow: $0.40 per share
• Price / Cash Flow: 27.57
• Book Value: $2.02 per share
• Price / Book: 5.51

Miscellaneous

• Outstanding Shares: 249,440,000
• Free Float: 235,222,000
• Market Cap: $2.78 billion
• Optionable: Optionable
• Beta: 1.18